Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
RESEARCH TOOLSreports
Holding RNA?
Track your performance easily
RNA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$11.23 - $56.00
Previous CloseN/A
Volume185.29K
Average Volume (3M)1.37M
Market Cap
$3.54B
Enterprise Value$4.09B
Total Cash (Recent Filing)$3.09M
Total Debt (Recent Filing)$7.58M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 04, 2025EPS Estimate
-0.79Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.90
Shares Outstanding119,309,320
10 Day Avg. Volume1,491,070
30 Day Avg. Volume1,367,014
Standard Deviation0.23
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)349.90
Price to Cash Flow (P/CF)-13.50
P/FCF Ratio0.00
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue403.84
Enterprise Value/Gross Profit427.37
Enterprise Value/Ebitda-14.19
Forecast
1Y Price Target
$66.38Price Target Upside103.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Avidity Biosciences News
Bulls Say, Bears Say
Bulls Say
Approval PathwaysRNA has confirmed with the FDA that the accelerated approval path is available for del-zota and the clinical data package can support a BLA filing.
Clinical TrialsThere is strong interest in enrollment for the DM1 phase 3 study, with completion on track, demonstrating confidence in the program.
Regulatory ProgressRNA is effectively engaging with FDA and global regulators on the FSHD regulatory path, indicating proactive management.
Bears Say
Clinical TrialsOne instance of anaphylaxis and an infusion reaction led to two discontinuations.
Data TransparencyMinimal information has been shared thus far about the novel DUX4 regulated endpoint.
Financial PerformanceRNA reported a net loss of $80.4 million for the third quarter.
---
Ownership Overview
1.57% Insiders
33.65% Mutual Funds
0.15% Other Institutional Investors
49.48% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
RNA FAQ
What was Avidity Biosciences Inc’s price range in the past 12 months?
Avidity Biosciences Inc lowest stock price was $11.23 and its highest was $56.00 in the past 12 months.
What is Avidity Biosciences Inc’s market cap?
Avidity Biosciences Inc’s market cap is $3.54B.
When is Avidity Biosciences Inc’s upcoming earnings report date?
Avidity Biosciences Inc’s upcoming earnings report date is Mar 04, 2025 which is in 31 days.
How were Avidity Biosciences Inc’s earnings last quarter?
Avidity Biosciences Inc released its earnings results on Nov 07, 2024. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.711 by $0.061.
Is Avidity Biosciences Inc overvalued?
According to Wall Street analysts Avidity Biosciences Inc’s price is currently Undervalued.
Does Avidity Biosciences Inc pay dividends?
Avidity Biosciences Inc does not currently pay dividends.
What is Avidity Biosciences Inc’s EPS estimate?
Avidity Biosciences Inc’s EPS estimate is -0.79.
How many shares outstanding does Avidity Biosciences Inc have?
Avidity Biosciences Inc has 119,309,320 shares outstanding.
What happened to Avidity Biosciences Inc’s price movement after its last earnings report?
Avidity Biosciences Inc reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.711. Following the earnings report the stock price went down -1.663%.
Which hedge fund is a major shareholder of Avidity Biosciences Inc?
Among the largest hedge funds holding Avidity Biosciences Inc’s share is RA Capital Management. It holds Avidity Biosciences Inc’s shares valued at 289M.
---
Avidity Biosciences Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.38 (103.43% Upside)
$66.38 (103.43% Upside)
Blogger Sentiment
Bullish
RNA Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 7.2%
Last 30 Days ▲ 7.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
192.02%
12-Months-Change
Fundamentals
Return on Equity
-18.66%
Trailing 12-Months
Asset Growth
186.27%
Trailing 12-Months
Company Description
Avidity Biosciences Inc
Avidity Biosciences Inc is a bio-technology company. The company develops novel Antibody Oligonucleotide Conjugates therapies designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Its product candidate AOC 1001, is designed to treat a rare monogenic muscle disease.
---
RNA Stock 12 Month Forecast
Average Price Target
$66.38
▲(103.43% Upside)
Technical Analysis
Best Analysts Covering RNA
1 Year
1 Year Success Rate
12/21 ratings generated profit
1 Year Average Return
+125.46%
reiterated a buy rating 18 days ago
Copying Yanan Zhu's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +125.46% per trade.
---